Search Login Register

lapatinib (GW572016) Summary

Description: an EGFR-ErbB-2 inhibitor

Also Known As: GW572016; GW 282974X; GW 572016; GW-282974X; GW-572016 Show All >>

Networked: 1024 relevant articles (162 outcomes, 354 trials/studies) for this Drug

Key Diseases for which lapatinib is Relevant

  1. Breast Neoplasms (Breast Cancer) : 103 outcomes 212 studies in 624 results
  2. Neoplasms (Cancer) : 34 outcomes 88 studies in 369 results
  3. Neoplasm Metastasis (Metastasis) : 20 outcomes 27 studies in 99 results
  4. Carcinoma (Carcinomatosis) : 4 outcomes 6 studies in 32 results
  5. Stomach Neoplasms (Stomach Cancer) : 3 outcomes 12 studies in 24 results
Show All >>

Drugs Related to lapatinib

  1. trastuzumab (Herceptin)
  2. capecitabine (Xeloda)
  3. Epidermal Growth Factor Receptor (EGF Receptor)
  4. Protein-Tyrosine Kinases (Tyrosine Kinase)
  5. Phosphotransferases (Kinase)
  6. Hormones
  7. letrozole (Femara)
  8. Aromatase (CYP19)
  9. Paclitaxel (Taxol)
  10. taxane
Show All >>

Therapies Related to lapatinib

  1. Drug Therapy (Chemotherapy)
  2. Heterologous Transplantation (Xenotransplantation)
  3. Aftercare (After-Treatment)
  4. Neoadjuvant Therapy
  5. Radiotherapy
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.